Q2 2021

Source filing unavailable

Q2 2021 · —

Revenue

$674.00K

no prior Q2 2020 on file

Net Income

-$3.91M

no prior Q2 2020 on file

EPS Diluted

$0.12

no prior Q2 2020 on file

Operating Income-$4,450,000—

Operating Cash Flowderived-$4,668,000—

Same quarter

Metric	Q2 2021	Q2 2019	Q2 2018	Q2 2017
Revenue	$674.00K	$666.00K	$604.00K	$611.00K
Net Income	-$3.91M	$3.70M	-$2.92M	-$3.18M
EPS Diluted	$0.12	$0.21	$0.20	$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR